David S. Snyder Purchases 1,800 Shares of Coya Therapeutics, Inc. (NASDAQ:COYA) Stock

Coya Therapeutics, Inc. (NASDAQ:COYA) CFO David S. Snyder purchased 1,800 shares of Coya Therapeutics stock in a transaction dated Thursday, November 14th. The shares were purchased at an average price of $7.19 per share, for a total transaction of $12,942.00. Following the completion of the acquisition, the chief financial officer now owns 8,800 shares of the company’s stock, valued at approximately $63,272. The trade was a 25.71 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Coya Therapeutics Price Performance

Shares of COYA stock opened at $6.32 on Friday. The stock has a market capitalization of $105.61 million, a PE ratio of -9.72 and a beta of 0.46. The business’s 50 day simple moving average is $7.12 and its 200 day simple moving average is $7.00. Coya Therapeutics, Inc. has a one year low of $4.75 and a one year high of $10.69.

Coya Therapeutics (NASDAQ:COYA) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.15. As a group, research analysts expect that Coya Therapeutics, Inc. will post -1.15 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have issued reports on COYA. HC Wainwright restated a “buy” rating and issued a $18.00 price target on shares of Coya Therapeutics in a research report on Monday, November 11th. Chardan Capital restated a “buy” rating and issued a $14.00 price objective on shares of Coya Therapeutics in a report on Thursday, November 7th.

Institutional Trading of Coya Therapeutics

A number of institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in shares of Coya Therapeutics by 772.3% in the 1st quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock valued at $8,407,000 after purchasing an additional 750,338 shares during the period. Renaissance Technologies LLC bought a new stake in Coya Therapeutics in the second quarter worth approximately $101,000. GHP Investment Advisors Inc. bought a new stake in Coya Therapeutics in the third quarter worth approximately $169,000. Gilbert & Cook Inc. bought a new position in shares of Coya Therapeutics during the 2nd quarter worth approximately $61,000. Finally, Geode Capital Management LLC grew its position in shares of Coya Therapeutics by 3.3% during the 3rd quarter. Geode Capital Management LLC now owns 142,309 shares of the company’s stock worth $918,000 after buying an additional 4,485 shares during the period. Institutional investors own 39.75% of the company’s stock.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.